Charles River Laboratories International, Inc

Pharmaceuticals
CRL
$ 187 2.7
Share price
$ 9.5 bn
Market Cap
$ 13 bn
Enterprise Value

Carbon footprint

10 Ton
GHG emissions per $ 1 mln investment
0.26x the weighted average for S&P 500
FY2021
How is this calculated?
+1.5%
YOY change in GHG emissions
Weaker than the +4.9% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-3.7%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

Charles River Laboratories International, Inc aims to reduce Scope 1 + 2 by 50% by 2030 from a base year 2018


This target has not been verified as science based according to SBTi
Charles River Laboratories International, Inc's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

Secondary Climate Goal

-3.1%
Proj. YOY change in GHG emissions (Scope 3)
Weaker than the -6.2% weighted average for S&P 500
FY2022
How is this calculated?

Charles River Laboratories International, Inc aims to reduce Scope 3 by 15% by 2030 from a base year 2019


This target has not been verified as science based according to SBTi
Charles River Laboratories International, Inc's actual and proj. GHG emissions (Scope 3) (Kt of CO2e)

GHG emissions and Carbon intensity

Charles River Laboratories International, Inc's GHG emissions (market-based) (Kt of CO2e)
Charles River Laboratories International, Inc's Carbon intensity (Tons per 1 USDm)

Charles River Laboratories International, Inc's carbon footprint

Charles River Laboratories International, Inc reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 132 Kt (+2/+1.5% y-o-y). At the sime time, carbon intensity was down at 45 t (-7 /-13.6% y-o-y).

Charles River Laboratories International, Inc's Scope 3 emissions skyrocketed to 343 Kt (+43/+14% y-o-y). The growth accelerated compared to the long-term upward trend (CAGR of +5.7% since 4Q'19).

The company is committed to reducing Scope 1 + 2 by 50% by 2030 from a base year 2018, which translates into the estimated reduction of -4.9 Kt per annum over the period of FY2022 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Also, the company commits to reducing Scope 3 by 15% by 2030 from a base year 2019, which translates into the estimated reduction of -11 Kt per annum over the period of FY2022 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...